Skip to main content

Advertisement

SpringerLink
Log in

Indirect comparison of etanercept, infliximab, and adalimumab for psoriatic arthritis: mixed treatment comparison using placebo as common comparator

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

Psoriatic arthritis (PsA) is a chronic inflammatory joint disorder that is commonly associated with skin psoriatic lesions and can lead to severe disability. Current pharmacologic therapy for PsA includes TNFα-blocking agents for patients who are intolerant of or have an inadequate response to conventional disease-modifying antirheumatic drugs. Currently, there are no published randomized controlled trials providing a head-to-head comparison of the effectiveness of the three TNFα-blocking agents used most often to treat patients with PsA (adalimumab, etanercept, and infliximab). In this study, we have performed the first indirect comparison among these biologic agents, in this setting, using a mixed treatment comparison analysis of the data from pivotal trials regarding efficacy profiles of adalimumab, etanercept, and infliximab evaluated as American College of Rheumatology (ACR) 20 response. Our results suggest that etanercept is expected to provide the greatest ACR20 response among the anti-TNFα agents compared with placebo in the treatment of patients with PsA unresponsive to conventional treatments. This analysis may be relevant for clinical decision-making, hence improving the management of PsA patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Jansen JP, Crawford B, Bergman G et al (2008) Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons. Value Health 11:956–964

    Article  PubMed  Google Scholar 

  2. Ades AE, Sculpher M, Sutton A et al (2006) Bayesian methods for evidence synthesis in cost-effectiveness analysis. PharmacoEconomics 24(1):1–19

    Article  PubMed  CAS  Google Scholar 

  3. Ades AE, Welton N, Lu G (2007) Introduction to mixed treatment comparisons. University of Bristol, Bristol, UK. https://www.bris.ac.uk/cobm/docs/intro%20to%20mtc.doc

  4. Caldwell D, Ades A, Higgins J (2005) Simultaneous comparison of multiple treatments: combining direct and indirect evidence. Br Med J 331(7521):897–900

    Article  Google Scholar 

  5. Lu G, Ades AE (2004) Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 23(20):3105–3124

    Article  PubMed  CAS  Google Scholar 

  6. Nixon RM, Bansback N, Brennan A (2007) Using mixed treatment comparisons and meta-regression to perform indirect comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritis. Stat Med 26(6):1237–1254

    Article  PubMed  CAS  Google Scholar 

  7. Bergman GJ, Hochberg MC, Boers M, Wintfeld N, Kielhorn A, Jansen JP (2010) Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs. Semin Arthritis Rheum 39(6):425–441

    Article  PubMed  CAS  Google Scholar 

  8. Genovese MC, Mease PJ, Thomson GT, Kivitz AJ, Perdok RJ, Weinberg MA, Medich J, Sasso EH (2007) Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. J Rheumatol 34(5):1040–1050

    PubMed  CAS  Google Scholar 

  9. Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, Furst DE, Molitor J, Keystone E, Gladman D, Manger B, Wassenberg S, Weier R, Wallace DJ, Weisman MH, Kalden JR, Smolen J (2005) Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 52(4):1227–1236, Erratum in: Arthritis Rheum 52 (9):2951

    Article  PubMed  CAS  Google Scholar 

  10. Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, Salonen D, Rubenstein J, Sharp JT, Tsuji W (2004) Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 50(7):2264–2272

    Article  PubMed  CAS  Google Scholar 

  11. Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH, Sharp JT, Ory PA, Perdok RJ, Weinberg MA (2005) Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 52(10):3279–3289

    Article  PubMed  CAS  Google Scholar 

  12. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, Katz LM, Lightfoot R Jr, Pauls H, strand V et al (1995) American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38(6):727–735

    Article  PubMed  CAS  Google Scholar 

  13. Cooper NJ, Sutton AJ, Lu G, Khunti K (2006) Mixed comparison of stroke prevention treatments in individuals with non rheumatic atrial fibrillation. Arch Intern Med 166:1269–1275

    Article  PubMed  Google Scholar 

  14. Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JPT, Churchill R, Watanabe N, Nakagawa A, Omori IM, McGuire H, Tansella M, Barbui C (2009) Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 373:746–758

    Article  PubMed  CAS  Google Scholar 

  15. Welton N, Caldwell D, Adamopoulous E, Vedhara K (2009) Mixed treatment comparison meta-analysis of complex interventions: psychological interventions in coronary heart disease. Am J Epidemiol 169:1158–1165

    Article  PubMed  Google Scholar 

  16. Jansen JP, Bergman GJ, Huels J, Olson M (2009) Prevention of vertebral fractures in osteoporosis: mixed treatment comparison of bisphosphonate therapies. Curr Med Res Opin 25(8):1861–1868

    Article  PubMed  CAS  Google Scholar 

  17. Saad AA, Symmons DP, Noyce PR, Ashcroft DM (2008) Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and meta-analysis of randomized controlled trials. J Rheumatol 35(5):883–890

    PubMed  CAS  Google Scholar 

  18. Wiens A, Venson R, Correr CJ, Otuki MF, Pontarolo R (2010) Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis. Pharmacotherapy 30(4):339–353

    Article  PubMed  CAS  Google Scholar 

  19. Saad AA, Ashcroft DM, Watson KD, Hyrich KL, Noyce PR, Symmons DP (2009) Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register. Arthritis Res Ther 11(2):R52

    Article  PubMed  Google Scholar 

  20. Kristensen LE, Gulfe A, Saxne T, Geborek P (2008) Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register. Ann Rheum Dis 67:364–369

    Article  PubMed  CAS  Google Scholar 

  21. Gomez-Reino JJ, Carmona L (2006) Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther 8:R29

    Article  PubMed  Google Scholar 

  22. Kalb RE, Gurske J (2005) Infliximab for the treatment of psoriasis: clinical experience at the State University of New York at Buffalo. J Am Acad Dermatol 53(4):616–622

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

The entire study was conducted with unrestricted funds from ANTIAGE (a nonprofit national association for ultrasound-guided intra-articular hip therapy) whose president is Prof. Alberto Migliore. Prof. Alberto Migliore and Prof. Bruno Laganà received grants as consultants from Pfizer, Abbott, and Merck for national and international studies and courses.

Disclosures

None.

Author information

Authors and Affiliations

  1. UO of Rheumatology, S. Pietro Fatebenefratelli Hospital, Via cassia 600, 00189, Rome, Italy

    Alberto Migliore & Emanuele Bizzi

  2. Research Center, S.Pietro Fatebenefratelli Hospital, Rome, Italy

    Alberto Migliore

  3. Bioikos Pharma, s.r.l, Bologna, Italy

    Serena Broccoli

  4. Rheumatology, 2nd Medical School, La Sapienza University, Rome, Italy

    Bruno Laganà

Authors
  1. Alberto Migliore
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Emanuele Bizzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Serena Broccoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bruno Laganà
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alberto Migliore.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Migliore, A., Bizzi, E., Broccoli, S. et al. Indirect comparison of etanercept, infliximab, and adalimumab for psoriatic arthritis: mixed treatment comparison using placebo as common comparator. Clin Rheumatol 31, 133–137 (2012). https://doi.org/10.1007/s10067-011-1790-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-011-1790-6

Keywords

Search

Navigation